Yasumichi Kuwahara
Kyoto, 6028566, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia.
Journal: Diseases (Basel, Switzerland)
Published: November 11, 2024
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia.
Journal: Scientific reports
Published: July 26, 2024
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
Journal: bioRxiv : the preprint server for biology
Published: May 20, 2024
Behavioral problems in adolescents and young adults with neurodevelopmental disorders.
Journal: Pediatrics international : official journal of the Japan Pediatric Society
Published: May 14, 2024
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
Journal: The Journal of clinical investigation
Published: May 01, 2024
Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma.
Journal: International journal of clinical oncology
Published: January 04, 2024
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.
Journal: bioRxiv : the preprint server for biology
Published: February 17, 2023
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Journal: Cancer discovery
Published: February 06, 2023
Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.
Journal: Molecular therapy oncolytics
Published: January 19, 2022
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.
Journal: Molecules and cells
Published: November 23, 2021
C11orf21, a novel RUNX1 target gene, is down-regulated by RUNX1-ETO.
Journal: BBA advances
Published: October 28, 2021
Last Updated: 09/26/2026